Drug firm Lupin on Monday said it has launched Rufinamide Tablets, an anticonvulsant medication, in the American market.
The company has launched the product, a generic version of Eisai Inc's Banzel tablets, in 200 mg and 400 mg strengths, the drug firm said in a statement.
As per IQVIA data, Rufinamide tablets had estimated annual sales of $138 million in the U.S.
Shares of the company were trading 0.81% down at Rs 769.05 apiece on the BSE.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
